Chia Tai Enterprises International Limited (3839.HK)
HKD 1.7
(-1.16%)
HKD 1.7
(-1.16%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 20.05 Million USD | 63.57% |
| 2022 | 12.25 Million USD | -24.74% |
| 2021 | 16.28 Million USD | 77.63% |
| 2020 | 9.16 Million USD | 32.14% |
| 2019 | 6.93 Million USD | -27.51% |
| 2018 | 9.57 Million USD | 211.39% |
| 2017 | 3.07 Million USD | 138.43% |
| 2016 | -8 Million USD | -792.64% |
| 2015 | 1.15 Million USD | -52.21% |
| 2014 | 2.41 Million USD | -34.45% |
| 2013 | 3.68 Million USD | 36.35% |
| 2012 | 2.7 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 19.21 Million USD | -27.34% |
| 2024 Q1 | 26.44 Million USD | 31.88% |
| 2023 Q3 | 15.1 Million USD | 4.98% |
| 2023 Q1 | 14.99 Million USD | 22.3% |
| 2023 FY | 20.05 Million USD | 63.57% |
| 2023 Q4 | 20.05 Million USD | 32.73% |
| 2023 Q2 | 14.38 Million USD | -4.02% |
| 2022 Q4 | 12.25 Million USD | -16.16% |
| 2022 Q1 | 14.75 Million USD | -9.43% |
| 2022 Q2 | 11.4 Million USD | -22.71% |
| 2022 FY | 12.25 Million USD | -24.74% |
| 2022 Q3 | 14.62 Million USD | 28.23% |
| 2021 Q2 | 15.56 Million USD | 4.64% |
| 2021 FY | 16.28 Million USD | 77.63% |
| 2021 Q4 | 16.28 Million USD | 1.8% |
| 2021 Q1 | 14.87 Million USD | 62.21% |
| 2021 Q3 | 15.99 Million USD | 2.8% |
| 2020 Q3 | 5.76 Million USD | 4.05% |
| 2020 Q2 | 5.53 Million USD | -18.84% |
| 2020 Q4 | 9.16 Million USD | 59.16% |
| 2020 Q1 | 6.82 Million USD | -1.69% |
| 2020 FY | 9.16 Million USD | 32.14% |
| 2019 Q2 | 8.37 Million USD | -14.6% |
| 2019 FY | 6.93 Million USD | -27.51% |
| 2019 Q1 | 9.8 Million USD | 2.48% |
| 2019 Q4 | 6.93 Million USD | -13.77% |
| 2019 Q3 | 8.04 Million USD | -3.94% |
| 2018 Q3 | - USD | -100.0% |
| 2018 FY | 9.57 Million USD | 211.39% |
| 2018 Q1 | 3.18 Million USD | 3.68% |
| 2018 Q4 | 9.57 Million USD | 0.0% |
| 2018 Q2 | 3.02 Million USD | -5.21% |
| 2017 Q4 | 3.07 Million USD | 2.26% |
| 2017 FY | 3.07 Million USD | 138.43% |
| 2017 Q3 | 3 Million USD | 131.09% |
| 2017 Q2 | -9.66 Million USD | 0.0% |
| 2017 Q1 | - USD | 100.0% |
| 2016 FY | -8 Million USD | -792.64% |
| 2016 Q4 | -8 Million USD | 0.0% |
| 2016 Q2 | 564 Thousand USD | -2.93% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q1 | 581 Thousand USD | -49.7% |
| 2015 Q4 | 1.15 Million USD | -2.12% |
| 2015 Q3 | 1.18 Million USD | -34.95% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q2 | 1.81 Million USD | 0.0% |
| 2015 FY | 1.15 Million USD | -52.21% |
| 2014 Q4 | 2.41 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 2.41 Million USD | -34.45% |
| 2013 FY | 3.68 Million USD | 36.35% |
| 2012 FY | 2.7 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -867.198% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 97.975% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 82.881% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 92.741% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 71.615% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 44.393% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -56.628% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 75.275% |
| SSY Group Limited | 1.94 Billion HKD | 98.971% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 54.224% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 96.614% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.879% |